Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time

Autor: Junwoo Bae, Hyunwoo Kim, Woosun Kim, Suhee Kim, Jinho Park, Dong‐In Jung, Dohyeon Yu
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Journal of Veterinary Internal Medicine, Vol 33, Iss 3, Pp 1322-1330 (2019)
Druh dokumentu: article
ISSN: 1939-1676
0891-6640
DOI: 10.1111/jvim.15478
Popis: Abstract Background The chromogenic anti‐Xa assay, the gold standard for monitoring the anti‐Xa effect of rivaroxaban, is not available as a cage‐side diagnostic test for use in a clinical setting. Hypothesis/Objectives To evaluate clinical modalities for measuring the anticoagulant effects of rivaroxaban using a point‐of‐care prothrombin time (PT) and thromboelastography (TEG). Animals Six healthy Beagle dogs. Methods Prospective, experimental study. Four different doses of rivaroxaban (0.5, 1, 2, and 4 mg/kg) were administered PO to dogs. Single PO and 3 consecutive dosing regimens also were assessed. Plasma rivaroxaban concentration was determined using a chromogenic anti‐Xa assay, point‐of‐care PT, and TEG analysis with 4 activators (RapidTEG, 1 : 100 tissue factor [TF100], 1 : 3700 tissue factor [TF3700], and kaolin), and results were compared. Spearman correlation coefficients were calculated between ratios (peak to baseline PT; peak reaction time [R] of TEG to baseline [R] of TEG) and anti‐Xa concentration. Results Anti‐Xa concentration had a significant correlation with point‐of‐care PT (R = 0.82, P
Databáze: Directory of Open Access Journals
Externí odkaz: